ValiRx plc (EAJF) AI Stock Analysis

0 Followers

ValiRx plc

(Frankfurt:EAJF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Very Low LeverageMinimal debt materially reduces interest and refinancing pressure while preserving financial flexibility. This provides some resilience as the company funds development activities, although the benefit is limited by ongoing losses and the shrinking equity base.

Negative Factors

Minimal and Declining RevenueRevenue remains far too small to support the current cost base and has declined materially year over year. This limits internal funding capacity, leaves the business dependent on future development success, and indicates that commercial scale has not yet been established.

ValiRx plc (EAJF) vs. iShares MSCI Germany ETF (EWG)

Not enough price history over this period.

Market Cap: EUR 2.11M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.8
Beta (1Y): -3.92
Revenue Growth: -36.78%
EPS Growth: 58.04%
Country: Germany
Employees: 11
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

ValiRx plc Business Overview & Revenue Model

Company Description

ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to treat p...

ValiRx plc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:EAJF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:HEMO	48Neutral	GBP 41.73M	-3.23	-409.57%	―	―	18.57%
GB:SAR	47Neutral	GBP 24.54M	-6.14	-188.01%	―	―	28.78%
GB:IMM	44Neutral	GBP 20.31M	-2.40	-559.87%	―	―	5.62%
GB:SCLP	43Neutral	GBP 103.04M	-4.79	128.87%	―	-100.00%	-30.39%
GB:TCF	42Neutral	GBP 4.64M	-1.70	-93.92%	―	―	55.56%

* Healthcare Sector Average

Performance Comparison

DE:EAJF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:EAJF	ValiRx plc	―	―	―
GB:TCF	Evgen Pharma	0.17	-0.04	-19.05%
GB:IMM	ImmuPharma plc	3.00	-7.40	-71.11%
GB:SAR	Sareum Holdings	14.75	0.25	1.72%
GB:SCLP	Scancell Holdings	83.80	-16.20	-16.20%
GB:HEMO	Hemogenyx Pharmaceuticals Plc	585.00	-425.00	-42.08%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

ValiRx plc AI Stock Analysis